Trials / Terminated
TerminatedNCT02831205
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- Duk-Woo Park, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ABSORB bioresorbable vascular scaffold is non-inferior to XIENCE everolimus-eluting cobalt-chromium stent with respect to target-lesion failure (TLF) at 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | everolimus-eluting bioresorbable vascular (Absorb) scaffold | |
| DEVICE | everolimus-eluting cobalt-chromium (Xience) stent |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-07-13
- Last updated
- 2017-12-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02831205. Inclusion in this directory is not an endorsement.